TCRR
TCR2 Therapeutics, Inc. (TCRR)
$1.30.78%▲
Live
Key Stats
$1.3
Day's Range
$1.4
$1.23
52-Week Range
$5.54
| Returns | |
| 1 month return | 17.31% |
| 3 month return | 56.86% |
| 1 year return | 74.76% |
| 5 year return | 91.44% |
Company Information
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
| Organization | TCR2 Therapeutics, Inc. |
| Employees | 105 |
| CEO | Dr. Garry E. Menzel M.B.A., Ph.D. |
| Industry | Pharmaceuticals: Major |
Analyst Recommendation
based on 10 analysts ratings
Buy
80%
Buy
20%
Hold
0%
Sell
Based on 10 Wall street analysts offering stock ratings for TCR2 Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 797.69%Current
$1.3
Target
$11.67
Recommendation Trend
Based on 10 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 8 | 11 | 11 |
| Hold | 2 | 4 | 4 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Highlights
| Market Capitalization | 49.1M |
| Book Value | $5.14 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -2.8 |
| Wall Street Target Price | 11.67 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.25 |
| Enterprise Value | -69049104 |
| Enterprise Value/Revenue | 0.0 |
| Enterprise Value/Ebitda | 0.59 |
Technicals
| Beta | 1.76 |
| 50 Day MA | 1.62 |
| 200 Day MA | 2.48 |
Institutional Holdings
Mpm Asset Management, LLC
10.48%
TANG CAPITAL MANAGEMENT LLC
9.42%
MPM Oncology Impact Management LP
8.72%
Vanguard Group Inc
3.45%
Redmile Group, LLC
2.83%
K2 PRINCIPAL FUND LP
2.79%
Discover more
Frequently Asked Questions
What is TCR2 Therapeutics, Inc. share price today?
Can Indians buy TCR2 Therapeutics, Inc. shares?
How can I buy TCR2 Therapeutics, Inc. shares from India?
Can Fractional shares of TCR2 Therapeutics, Inc. be purchased?
What are the documents required to start investing in TCR2 Therapeutics, Inc. stocks?
What are today’s High and Low prices of TCR2 Therapeutics, Inc.?
What are today’s traded volumes of TCR2 Therapeutics, Inc.?
What is today’s market capitalisation of TCR2 Therapeutics, Inc.?
What is the 52 Week High and Low Range of TCR2 Therapeutics, Inc.?
How much percentage TCR2 Therapeutics, Inc. is down from its 52 Week High?
How much percentage TCR2 Therapeutics, Inc. is up from its 52 Week low?
What are the historical returns of TCR2 Therapeutics, Inc.?
Who is the Chief Executive Officer (CEO) of TCR2 Therapeutics, Inc.?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*